MOLN Molecular Partners: Projected Price to Earnings

Public company logo of molecularpartners.com (MOLN)

The market dynamics of the P/E ratio for Molecular Partners AG (MOLN) reflected in the price action is 0.00. Molecular Partners AG develops innovative methods for combating tumors. Its success relies on payments from AbbVie, the development of its own research, and the value of a unique development pipeline. Meanwhile, production resources are functioning stably, and the modernization of protein synthesis systems ensures the reliability of all technological stages.

Molecular Partners - MOLN Future Price to Earnings Multiple (period 07/04/2022 - 11/14/2026)

Analytical breakdowns for molecularpartners.com (MOLN)

- stock quotes and analyst forecast:
Stock Price Molecular Partners AG|MOLN - Analyst Target Range
- company stock capitalization data:
Market Valuation Molecular Partners Ltd|MOLN - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Molecular Partners|MOLN - Accounting Value of Company|Market Value to Book Value Ratio molecularpartners.com|MOLN - Total Asset Value of Company
- debt level and financial liquidity data:
Debt to Equity Molecular Partners AG|MOLN - Long-Term Debt to Equity|Short-Term Debt to Capital Molecular Partners|MOLN - Company Aggregate Debts|Debt to Book Value Molecular Partners Ltd|MOLN - Amount of Long-Term Liabilities|Company Short-Term Debts Molecular Partners|Quick Liquidity molecularpartners.com
- financial results and valuation multiples details:
MOLN - Company Net Income|Expected Profit Molecular Partners AG|MOLN - Company Value to Net Income|Future Price to Earnings Molecular Partners AG|MOLN - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners Ltd|MOLN - Operating income before deduction of amortization|Earnings per share for the last twelve months Molecular Partners|MOLN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months molecularpartners.com|MOLN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Molecular Partners AG
- sales volume and revenue information:
MOLN - Company Revenue|Projected Sales Volume Molecular Partners|MOLN - Price to Sales|Forward P/S Multiple Molecular Partners Ltd
Comprehensive company analysis:Molecular Partners AG MOLN
Signature product of molecularpartners.com

For Molecular Partners AG, valuation based on expected earnings reflects the market premium for the exclusivity of the DARPin platform. This metric compares the current share price with updated net income forecasts, identifying pivotal turning points in the business valuation. By analyzing the company's projected P/E value, an investor determines the extent of the premium paid for innovation. Low values create a defensive buffer but may signal stagnation. The indicator's final balance determines the risk of capital freeze.

Key competitors

Forward P/E Multiple GERN|Nanobiotix SA (NBTX) - Forward Price to Earnings Multiple|Bicycle Pharma - Projected Price to Earnings|CytomX Corp (CTMX) - Projected Price to Earnings Ratio|CATX: Projected Price to Earnings|Future Price to Earnings Multiple GNLX (Genelux Corporation)|oncolyticsbiotech.com (ONCY) - Future Price to Earnings|Price to Expected Earnings Ratio LSTA (Lisata Therapeutics, Inc.)|Future Price to Earnings Moleculin Biotech Inc|Future Price to Earnings GRTX|Forward P/E Multiple MTEM